gener
safe
vaccinia
tian
tan
vtt
base
vaccin
vector
necessari
develop
method
attenu
viru
modifi
vtt
mvtt
construct
replac
viral
gene
gfp
gene
comparison
parent
vtt
mvtt
lost
replic
capac
rabbit
human
hela
cell
line
life
cycl
viral
replic
block
differ
stage
two
cell
line
determin
electron
microscop
examin
mvtt
less
virul
vtt
measur
mous
bodi
weight
loss
intranas
viral
inocul
determin
intracrani
ld
valu
mice
foreign
gfp
gene
stabl
genet
round
passag
vero
cell
importantli
mvtt
elicit
humor
cellmedi
immun
respons
gfp
gene
mice
two
intramuscular
inocul
pfu
viru
antigfp
antibodi
reciproc
endpoint
titer
reach
determin
elisa
number
secret
cell
reach
sfu
per
million
splenocyt
cellspecif
epitop
gfp
collect
remov
gene
use
method
gener
attenu
vaccinia
tian
tan
vaccin
vector
declar
worldwid
erad
smallpox
vaccinia
viru
studi
use
live
viral
vector
infecti
diseas
cancer
therapi
moss
mwau
et
al
paoletti
peopl
repubabbrevi
vtt
vaccinia
tian
tan
mvtt
modifi
vaccinia
tian
tan
mva
modifi
vaccinia
ankara
gfp
green
fluoresc
protein
aid
acquir
immunodefici
syndrom
human
immunodefici
viru
type
one
siv
simian
immunodefici
viru
shiv
simianhuman
immunodefici
chimer
viru
ctl
cytotox
lymphocyt
moi
multipl
infect
pfu
plaqu
form
unit
pi
postinfect
em
electron
microscop
lic
china
vaccinia
tian
tan
vtt
strain
use
histor
smallpox
vaccin
million
peopl
yet
potenti
vaccin
vector
explor
care
fulllength
sequenc
vtt
genom
determin
jin
et
al
base
sequenc
comparison
vtt
display
genet
featur
distinct
vaccinia
virus
includ
vaccinia
western
reserv
wr
strain
hou
et
al
jin
et
al
tsao
et
al
particular
uniqu
delet
insert
affect
multipl
gene
identifi
restrict
enzym
hindiiic
b
fragment
data
infer
plausibl
distinct
biolog
properti
vtt
jin
et
al
recent
biolog
properti
vtt
character
term
host
cell
rang
growth
properti
vitro
virul
vivo
fang
et
al
although
vtt
significantli
less
virul
vaccinia
wr
strain
remain
lethal
mice
intracrani
inocul
caus
signific
bodi
weight
loss
intranas
inocul
fang
et
al
properti
limit
use
vaccin
vector
human
use
especi
immunesuppress
individu
therefor
attenu
vtt
necessari
develop
use
vaccin
vector
variou
viral
vector
system
evalu
vaccin
develop
santra
et
al
tartaglia
et
al
poxviru
vector
live
recombin
vector
studi
intens
wide
studi
vacciniabas
vector
probabl
modifi
vaccinia
viru
ankara
mva
vector
safe
human
even
immunocompromis
individu
cosma
et
al
moreov
mvabas
vaccin
effect
induc
protect
respons
differ
virus
sever
acut
respiratori
syndrom
coronaviru
influenza
respiratori
syncyti
viru
bisht
et
al
chen
et
al
de
waal
et
al
degano
et
al
olszewska
et
al
sutter
et
al
wyatt
et
al
mvabas
vaccin
also
effect
delay
develop
aid
progress
diseas
rhesu
monkey
infect
simian
immunodefici
viru
siv
simianhuman
immunodefici
viru
shiv
barouch
et
al
howev
immunogen
profil
mva
vaccin
vector
unsatisfactori
human
recent
phase
one
trial
indic
mvabas
vaccin
immunogen
human
goonetillek
et
al
therefor
desir
explor
potenti
vacciniabas
vector
system
stimul
stronger
host
immun
respons
human
studi
method
gener
modifi
vtt
mvtt
describ
method
involv
genet
modif
parent
vtt
genom
delet
gene
includ
one
host
rang
gene
rational
choos
gene
delet
correspond
lost
gene
delet
ii
region
mva
genom
antoin
et
al
meyer
et
al
studi
unknown
extent
vaccinia
viru
could
attenu
remov
gene
delet
ii
region
mva
serv
ideal
insert
site
foreign
gene
effect
correspond
region
vtt
genom
express
foreign
gene
also
unknown
reason
phenotyp
chang
mvtt
comparison
parent
vtt
vitro
vivo
potenti
use
mvtt
live
viral
vector
vaccin
develop
examin
studi
thirteen
cell
line
variou
origin
maintain
growth
condit
suggest
american
type
cultur
collect
atcc
rockvil
md
cell
line
includ
wish
hela
rk
mdck
vero
primari
chicken
embryo
fibroblast
cef
prepar
embryo
parent
vaccinia
tian
tan
strain
obtain
institut
virolog
chines
center
diseas
control
prevent
vtt
strain
deriv
origin
chines
nation
institut
control
pharmaceut
biolog
product
nicpbp
viru
stock
propag
vero
cell
purifi
centrifug
sucros
cushion
viru
stock
titrat
plaqu
form
assay
use
crystal
violet
stain
shuttl
vector
construct
insert
two
genom
fragment
flank
delet
region
vtt
gfp
gene
place
synthet
earlyl
promot
p
syn
chakrabarti
et
al
wyatt
et
al
mvtt
viru
made
homolog
recombin
method
describ
previous
sutter
moss
sutter
et
al
wyatt
et
al
plaqu
express
gfp
select
purifi
subsequ
six
round
plaqu
purif
agaros
insert
recombin
viru
determin
nest
pcr
use
primer
pair
flank
delet
region
pcr
primer
use
test
sens
antisens
first
round
reaction
sens
antisens
second
round
reaction
amplif
cycl
c
min
follow
cycl
c
c
c
min
plu
last
extens
c
min
amplifi
pcr
product
purifi
use
qiaquick
pcr
purif
kit
qiagen
valencia
ca
usa
subject
dna
sequenc
directli
autom
abi
dna
sequenc
appli
biosystem
inc
foster
citi
ca
usa
comparison
recombin
vtt
gfp
gener
place
gfp
gene
locat
upstream
hemagglutinin
gene
without
artifici
interrupt
gene
assay
determin
viral
host
cell
rang
growth
properti
vitro
virul
mvtt
vivo
describ
previous
carrol
moss
fang
et
al
confluent
cell
monolay
infect
moi
vtt
viru
allow
attach
cell
min
c
cell
wash
medium
three
time
incub
c
addit
h
infect
cell
trypsin
detach
cultur
plate
wash
pb
twice
cell
pellet
fix
glutaraldehyd
process
examin
use
transmiss
electron
microscopi
routin
techniqu
describ
previous
wolff
et
al
sixround
purif
gfp
posit
plaqu
ten
addit
round
passag
viru
carri
last
passag
vero
cell
infect
subsequ
mvtt
moi
fortyeight
hour
infect
percentag
gfp
vaccinia
antigen
doubl
posit
plaqu
count
method
immunostain
vaccinia
specif
antigen
describ
previous
carrol
moss
balbc
mice
immun
mvtt
group
three
femal
balbc
mice
immun
intramuscularli
twice
pfu
mvtt
parent
type
vtt
l
pb
week
serum
sampl
collect
week
antigfp
antibodi
test
gambotto
et
al
hsu
et
al
antigfp
antibodi
endpoint
titer
determin
reciproc
highest
dilut
sampl
produc
least
twofold
greater
valu
correspond
optic
densiti
readout
control
serum
sampl
dilut
coat
antigen
recombin
histag
egfp
purifi
e
coli
nickel
column
chromatographi
week
mice
kill
splenocyt
isol
mice
measur
cellmedi
immun
respons
elispot
assay
kit
ucytech
netherland
epitop
hylstqsal
use
puls
antigen
gambotto
et
al
mice
receiv
pb
serv
neg
control
staphylococcu
aureu
enterotoxin
b
seb
use
posit
control
spot
count
use
elispot
reader
bioread
biosi
inc
germani
serial
twofold
dilut
heatinactiv
mous
serum
incub
pfu
parent
vtt
c
h
mix
solut
inocul
onto
vero
cell
plate
cell
overlay
agaros
min
viral
absorpt
h
incub
c
viral
plaqu
visual
crystal
violet
stain
count
antibodi
titer
defin
reciproc
serum
dilut
reduc
viral
plaqu
serum
sampl
preimmun
mockimmun
anim
includ
background
control
use
homolog
recombin
method
gfp
gene
introduc
vtt
genom
gener
mvtt
introduct
gfp
gene
replac
fragment
viral
genom
posit
base
vtt
genbank
access
number
replac
result
delet
viral
gene
tabl
drillien
et
al
replac
success
plaquepurifi
gfp
posit
viru
test
specif
pcr
immunochem
stain
subsequ
sequenc
analysi
data
shown
seri
plaqu
purif
pure
viral
stock
mvtt
gener
determin
coexpress
gfp
vaccinia
specif
antigen
data
shown
determin
effect
delet
vtt
gene
viral
biolog
properti
growth
kinet
mvtt
quantit
character
use
previous
describ
method
carrol
moss
thirteen
mammalian
cell
line
variou
host
origin
primari
chicken
embryo
fibroblast
cef
infect
mvtt
moi
cell
line
includ
wish
hela
rk
mdck
vero
sinc
cell
deriv
divers
host
tissu
origin
experi
determin
breadth
host
cell
rang
mvtt
comparison
parent
vtt
replic
properti
mvtt
chang
significantli
cell
line
includ
vero
wish
cef
exampl
mvtt
replic
well
vero
cell
fig
howev
replic
level
mvtt
drop
cell
line
includ
mdck
pk
hela
fig
tabl
particular
mvtt
seem
replic
hela
cell
overtim
result
indic
loss
viral
gene
like
signific
impact
growth
capac
viru
certain
cell
line
vitro
l
earli
ankyrinhost
rang
chung
et
al
gillard
et
al
perku
et
al
ramseyew
moss
shisler
jin
intermedi
serin
proteas
inhibitor
spi
prevent
cell
fusion
gambotto
et
al
hsu
et
al
law
smith
turner
moyer
zhou
et
al
carrol
moss
cell
infect
moi
b
viru
replic
fold
increas
viru
titer
determin
divid
viru
yield
h
input
titer
cell
line
therefor
categor
permiss
p
increas
semipermiss
sp
increas
nonpermiss
np
increas
carrol
moss
cell
infect
moi
immunostain
analysi
cell
infect
mvtt
conduct
determin
degre
celltocel
spread
order
understand
underlin
mechan
reduc
viral
growth
capac
mammalian
cell
line
cef
becam
infect
mvtt
infect
indic
express
specif
antigen
stain
polyclon
antivaccinia
serum
infect
cell
fig
compar
parent
vtt
strain
mvtt
spread
well
cell
line
includ
vero
wish
cef
mvtt
howev
display
restrict
spread
sever
cell
line
includ
mdck
fig
fewer
number
posit
cell
found
foci
h
pi
indic
viral
spread
via
celltocel
contact
less
effici
reduc
spread
capac
mvtt
via
celltocel
contact
like
reason
decreas
replic
kinet
cell
line
understand
viral
life
cycl
hela
cell
mvtt
parent
vtt
subject
em
examin
examin
morpholog
newli
produc
viral
particl
stage
viral
replic
blockad
cell
line
expect
resolv
hela
cell
analyz
around
h
pi
fig
shown
fig
neither
intracellular
matur
virion
imv
immatur
virion
iv
found
cell
infect
mvtt
howev
hela
cell
show
differ
result
fig
immatur
virion
often
found
cytoplasm
hela
cell
wherea
imv
could
identifi
control
cell
line
produc
major
viral
particl
characterist
brickshap
imv
cytoplasm
infect
parent
vtt
fig
therefor
data
indic
abort
viral
replic
two
cell
line
like
due
blockad
differ
stage
viral
replic
assembl
immatur
virion
cell
around
matur
time
imv
morphogenesi
hela
cell
vivo
virul
mvtt
evalu
inbr
balbc
mice
use
method
describ
previous
lee
et
al
betakova
et
al
zhang
et
al
viral
virul
first
determin
daili
measur
bodi
weight
chang
period
day
anim
inocul
viru
via
intranas
rout
five
mice
test
three
dose
group
pfu
per
mous
shown
fig
none
infect
mice
die
experi
although
mice
infect
mvtt
show
less
weight
loss
day
high
dose
group
pfu
viru
significantli
less
virul
parent
vtt
result
weight
loss
period
time
fang
et
al
interestingli
bodi
weight
chang
mice
infect
pfu
mvtt
similar
mice
given
pfu
parent
vtt
fig
result
suggest
mvtt
attenu
set
subsequ
neurovirul
mvtt
evalu
infect
balbc
mice
via
intracrani
rout
neurovirul
infect
mice
determin
measur
intracrani
lethal
infecti
dose
icld
six
mice
per
group
inocul
seri
fivefold
dilut
virus
start
pfu
count
number
dead
anim
daili
fig
icld
calcul
use
reedmuench
method
reed
muench
icld
mvtt
pfu
sinc
icld
parent
vtt
pfu
result
demonstr
mvtt
attenu
seri
passag
viru
conduct
vero
cell
order
determin
whether
mvtt
could
develop
novel
vaccin
vector
round
passag
antivaccinia
antibodi
use
stain
infect
foci
evalu
foci
display
gfp
express
data
shown
find
indic
foreign
gfp
gene
stabl
genom
mvtt
pure
gfpexpress
viru
may
enabl
gener
report
mvtt
base
vaccin
revers
gfp
select
crucial
elimin
redund
report
gene
vaccin
human
use
group
balbc
mice
inocul
viru
evalu
well
mvtt
could
use
vaccin
vector
immun
respons
foreign
protein
gfp
subsequ
determin
elisa
purifi
recombin
egfp
mvtt
induc
gfp
specif
antibodi
respons
respons
detect
first
immun
averag
serum
reciproc
titer
fig
second
immun
signific
boost
effect
averag
antibodi
respons
gfp
doubl
averag
serum
reciproc
titer
reach
level
antibodi
respons
similar
induc
control
recombin
vtt
gfp
fig
moreov
cellmedi
immun
respons
gfp
also
detect
elispot
assay
approxim
spotform
cell
sfc
per
million
splenocyt
detect
specif
ctl
epitop
hylstqsal
fig
immun
vtt
gfp
also
induc
fig
neutral
antibodi
respons
elicit
vtt
mice
immun
mvtt
vtt
serum
sampl
collect
week
pi
test
antibodi
titer
defin
reciproc
serum
dilut
reduc
viral
plaqu
bar
repres
averag
valu
three
sampl
deviat
serum
sampl
preimmun
mockimmun
anim
includ
background
control
experi
repeat
twice
similar
result
obtain
cellmedi
immun
respons
gfp
slightli
lower
level
contrast
immun
wild
type
vtt
placebo
induc
immun
respons
gfp
data
indic
mvtt
capabl
elicit
specif
immun
respons
foreign
antigen
vivo
like
compar
potenc
vtt
gfp
addit
immun
respons
gfp
neutral
antibodi
titer
parent
vector
vtt
also
evalu
consist
antibodi
respons
gfp
level
neutral
antibodi
respons
vtt
boost
significantli
second
immun
fig
slightli
higher
level
neutral
antibodi
induc
fig
humor
cellmedi
immun
respons
elicit
gfp
mice
immun
mvtt
mice
intramuscularli
inocul
pfu
mvtt
vtt
boost
interv
mice
receiv
pb
serv
control
sera
test
specif
igg
antibodi
gfp
elisa
day
week
pi
respons
week
anim
shown
absorb
readout
sampl
fell
cutoff
valu
use
determin
antibodi
titer
differ
mvtt
vtt
test
time
point
statist
signific
p
b
number
cell
specif
gfp
epitop
hylstqsal
determin
elispot
assay
bar
repres
averag
valu
three
sampl
deviat
differ
mvtt
vtt
week
pi
statist
signific
p
experi
repeat
twice
similar
result
obtain
vtt
mvtt
differ
howev
reach
statist
signific
therefor
remov
gene
seem
affect
major
neutral
determin
vaccinia
viru
mvtt
display
distinct
biolog
properti
compar
parent
vtt
first
mvtt
display
reduc
replic
capac
two
human
cell
line
hela
well
anim
cell
line
includ
pk
mdck
phenotyp
chang
found
like
relat
reduc
replic
celltocel
spread
capac
mvtt
hela
cell
line
becam
nonpermiss
mvtt
infect
em
examin
indic
life
cycl
mvtt
significantli
block
rel
earli
stage
assembl
immatur
virion
cell
stage
virion
matur
hela
cell
second
mvtt
much
less
virul
determin
two
separ
experi
bodi
weight
loss
found
day
pi
mice
receiv
high
dose
pfu
mvtt
via
intranas
rout
inocul
sinc
pfu
parent
vtt
caus
similar
level
bodi
weight
loss
mvtt
like
attenu
moreov
mvtt
display
increas
intracrani
ld
mice
via
intracrani
inocul
time
greater
parent
vtt
find
indic
mvtt
attenu
vaccinia
strain
attenu
essenti
futur
develop
safe
vaccin
vector
lee
et
al
moss
tartaglia
et
al
attenu
howev
seem
affect
express
foreign
antigen
gfp
variou
cell
type
infect
individu
properti
prerequisit
vacciniabas
vaccin
vector
gfp
gene
mvtt
may
serv
either
revers
select
marker
vaccin
construct
report
neutral
assay
phenotyp
chang
observ
mvtt
relat
loss
gene
vtt
genom
previou
studi
reveal
vtt
display
genet
featur
distinct
vaccinia
virus
hou
et
al
tsao
et
al
genet
featur
led
distinct
biolog
characterist
vtt
compar
vaccinia
wr
strain
fang
et
al
studi
four
vaccinia
gene
includ
three
earli
gene
well
one
intermedi
gene
remov
vtt
genom
gener
mvtt
four
gene
found
associ
virul
vaccinia
viru
vivo
previous
defin
host
rang
gene
essenti
vaccinia
viral
replic
cell
chung
et
al
perku
et
al
ramseyew
moss
consist
previou
find
mva
mvtt
replic
poorli
also
cell
sinc
gene
inhibit
apoptosi
cell
host
nfkappab
activ
shisler
jin
separ
studi
necessari
address
whether
gene
vtt
alon
would
similar
biolog
function
gene
encod
serin
proteas
inhibitor
inhibit
cellcel
fusion
law
smith
turner
moyer
zhou
et
al
delet
alon
chang
viru
replic
vitro
well
virul
immunogen
vivo
law
smith
turner
moyer
zhou
et
al
loss
gene
mvtt
induc
cellcel
fusion
everi
cell
type
test
fig
consist
previou
find
properti
enhanc
cell
fusion
increas
virul
mvtt
vivo
viru
attenu
instead
date
biolog
function
vaccinia
gene
remain
clear
suggest
previous
function
ankyrinlik
protein
shchelkunov
et
al
stage
although
loss
gene
result
format
attenu
mvtt
whether
four
gene
contribut
phenotyp
chang
remain
exclus
analysi
individu
gene
requir
obtain
definit
answer
nevertheless
loss
gene
affect
replic
mvtt
vero
cef
cell
sinc
attenu
virus
eg
mva
reli
sole
cef
cell
product
growth
properti
mvtt
vero
cell
may
offer
advantag
futur
manufactur
vero
one
fda
approv
cell
line
vaccin
product
develop
human
vaccin
vector
anticip
inactiv
addit
vtt
gene
involv
host
cell
rang
eg
viral
virul
eg
hemagglutinin
tk
etc
would
necessari
antoin
et
al
shida
et
al
mvtt
elicit
specif
immun
respons
foreign
antigen
gfp
use
attenu
vaccinia
viru
live
vaccin
vector
one
critic
question
whether
viru
still
immunogen
induc
specif
immun
respons
foreign
antigen
address
question
immun
respons
vector
foreign
antigen
determin
suboptim
dose
pfu
mvtt
vtt
induc
similar
level
neutral
antibodi
respons
vtt
fig
gfpspecif
humor
cellmedi
immun
respons
detect
level
respons
compar
induc
vtt
gfp
viru
sinc
gfp
appar
stabl
genom
mvtt
viru
develop
becom
live
vaccin
vector
infecti
pathogen
tumor
case
gene
encod
pathogen
tumor
specif
antigen
place
genom
locat
gfp
gene
futur
studi
compar
studi
use
mvtt
vaccinia
strain
eg
mva
essenti
reveal
fundament
differ
advantag
system
serv
vaccin
vector
consid
mvtt
remain
replicationcompet
sever
mammalian
cell
test
correl
dose
vaccin
efficaci
need
evalu
would
noninvas
mucos
rout
vaccin
latter
critic
inocul
vacciniabas
vaccin
via
mucos
rout
induc
immun
respons
foreign
gene
even
presenc
preexist
antivector
immun
belyakov
et
al
demonstr
mucos
inocul
vacciniaimmun
balbc
mice
recombin
vaccinia
express
induc
specif
serum
antibodi
strong
cytotox
lymphocyt
respons
live
viral
vaccin
vector
essenti
evad
preexist
antivector
immun
stimul
robust
immun
respons
site
viral
transmiss
eg
influenza
individu
receiv
smallpox
vaccin
born
preexist
antivector
immun
issu
